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ABSTRACT: Examples of organometallic compounds as nucleoside analogues are rare within the field of medicinal bioor-
ganometallic chemistry. We report on the synthesis and properties of two chiral ferrocene derivatives containing both a nucle-
obase and a hydroxyalkyl group. These so-called ferronucleosides show promising anticancer activity, with cytostatic studies 
on five different cancer cell lines indicating that both functional groups are required for optimal activity. 
Nucleoside analogues have long been established as an 
effective class of compound that exhibits antiviral or anti-
cancer activity.1 Two common structural features are a nu-
cleobase moiety and a hydroxylmethyl group (Figure 1), 
which together allow them to act as substrates that adversely 
affect processes associated with nucleic acid synthesis. 
These two components are typically connected by an organic 
linker group that is a modification or a replacement of the 
sugar ring, which can either be cyclic (e.g. AZT) or acyclic 
(e.g. acyclovir).2 Due to their structural similarities to natural 
nucleosides, which can lead to resistance and side-effects, 
there is a continuing need for a diverse range of analogues 
with different structural features. Ferrocene has attracted ac-
tive interest in recent years within the field of medicinal and 
bioorganometallic chemistry,3 with organometallic ana-
logues and derivatives of the antimalarial drug chloroquine 
(ferroquine) and the breast cancer drug tamoxifen (the ferro-
cifen family) being the most widely known.4 At the same 
time there has been a number of examples of other ferrocene 
containing compounds that have shown anticancer,5 antibac-
terial and antifungal properties.6 However although there are 
also some recent examples of ferrocene-conjugated nucleo-
bases7 and hydroxylalkyl ferrocenes8  that exhibit anticancer 
activity, as far as we are aware, nucleoside analogues of the 
type shown in Figure 1 that are bridged solely by an organ-
ometallic linker group and show biological activity have not 
been reported.9 
As part of our programme to develop novel metal-con-
taining analogues of DNA and its components,10 we recently 
reported an organometallic nucleic acid oligomer designated 
as Ferrocene Nucleic Acid (FcNA).10b The monomeric com-
ponents of the reported form of FcNA consist of a tetra-sub-
stituted ferrocene unit containing two alkyl hydroxyl groups 
to allow connectivity via phosphodiesters, and two thymine 
nucleobases. We noticed that these monomeric compounds 
have the required features for a novel nucleoside analogue, 
where the 5-membered sugar ring is substituted for a 5-mem-
bered cyclopentadienyl ring of a ferrocene unit. Accordingly 
we now report bis-substituted ferrocenes 1 and 2 (so-called 
ferronucleosides), that contain both a nucleobase (thymine 
or adenine) and a hydroxyl group, along with various control 
compounds (Fig. 2).  The cell line studies reported here 
demonstrate the promise of these ferrocenyl derivatives as a 
novel class of nucleoside analogue that show anticancer ac-
tivity. 
Figure 1. Schematic representation of the structural relationship 
between thymidine and a nucleoside analogue that contains a vari-
able linker group connecting a hydroxymethyl group with a nucle-
obase, with AZT (azidothymidine) as a specific example. 
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 Figure 2. Ferronucleosides 1 and 2 and controls 3-6. 
 
It was decided to first synthesize nucleoside analogues 
with a 1,2-disubstituted arrangement on one Cp ring, with 
the other Cp ring unfunctionalized. This would enable us to 
utilize the synthetic chemistry already developed within the 
group for FcNA monomer synthesis.10b For the same reason, 
the compounds would have a three-carbon hydroxyl linker 
(with a methyl group on the alpha carbon to direct ortho-
lithiation) and a two-carbon linker to the nucleobase. The 
synthetic route taken to make the ferronucleoside targets 1 
and 2 is outlined in Scheme 1. The chirally pure Ugi amine11 
7 was treated with n-BuLi and quenched with iodine to in-
troduce the required planar 1,2-disubstitution pattern. Sub-
sequent functional group inter-conversion gave compound 
11, to provide the chain extension giving a three carbon 
linker. Treatment of 11 with silyl enol ether, catalysized by 
the Lewis acid boron trifluoride, gave compound 12 in good 
yield. Reduction of the ester, followed by TBDPS protection 
gave compound 14. Conversion to aldehyde 15 (via n-BuLi 
halogen exchange and quenching with DMF) enabled a Wit-
tig reaction to be performed to from alkene 16, with subse-
quent hydroboration-oxidation giving the mono-protected 
bis-alcohol 17 in high chiral purity (as checked by chiral 
HPLC analysis, overall 97% ee). The conversion of 17 to the 
target compounds 1 and 2 proceeded via a Mitsunobu reac-
tion with the appropriate protected nucleobase, followed by 
deprotection of the protecting groups. The family of com-
pounds was also extended by making the control compounds 
3-6 (Fig. 2), to assess the role of the alcohol and nucleobase 
groups, noting that compound 6 had previously been shown8 
to display antineoplastic activity against cervix carcinoma 
(HeLa) tumor cells. 
The cytostatic activity of six ferrocene compounds was 
evaluated in comparison to the established anticancer drugs 
cisplatin and 5-fluorouracil (5-FU) using a proliferation ac-
tivity assay carried out on three tumor cell lines: murine leu-
kemia cells (L1210), HeLa, and human T-lymphocyte cells 
(CEM). The data indicate that the concomitant presence of 
both the hydroxyl and nucleobase components are of crucial 
importance to give the highest cytostatic activity, with 1 and 
2 exhibiting low to sub micromolar antiproliferative activity 
comparable with cisplatin (Table 1). In addition, 1 and 2 
were almost equally as active as 5-FU in L1210 cell cultures, 
2- to 5-fold less active in HeLa cell cultures, but 20-to 50-
fold more active in CEM cell cultures. Compounds 1 and 2 
proved poorly toxic to non-tumorigenic human embryonic 
lung (HEL) fibroblast cell cultures (minimal cytotoxic con-
centration: >50 µM).  
 
Scheme 1. Synthetic route towards ferrocene nucleoside an-
alogues 1 and 2. 
 
Table 1. Cytostatic activity of compounds 1-4. 
Compound 
IC50 (µM)a 
L1210 CEM HeLa 
1 0.78 0.9 2.68 
2 1.0 0.35 1.1 
3 12 39 45 
4 417 592 509 
5 26 49 94 
6 25 43 52 
Cisplatin 1 0.9 1.2 
5-FU 0.33  0.17 18  5 0.54  0.12 
a50% inhibitory concentration, or compound concentration re-
quired to inhibit tumor cell proliferation by 50%. Data are the mean 
of at least two independent experiments. 
Cell growth studies carried out on an oesophageal cancer 
cell line revealed that compound 1 inhibited growth at con-
centrations of 6.25 µM, whereas control compounds 3 and 4 
(Figure 3 and supplementary data respectively) had much 
less or no effect, even up to higher concentrations of 25 µM. 
The same trend was observed for the adenine compound 2 
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 and its control 5 (see supplementary data). Once again the 
data indicates that both functional groups (the hydroxyl in 
addition to the nucleobase) are required for the best cyto-
static activities, which is comparable to cisplatin under these 
conditions. 
Assays of cellular viability (MTT assay) and cell prolif-
eration (BrdU assay) were then performed on colorectal can-
cer cell lines. The results after 48hr exposure (Figure 4) re-
vealed that compounds 1 and 2 had anti-neoplastic activities 
approaching that 5-FU, whereas the other compounds were 
less effective. Encouragingly, an AMES assay to investigate 
the potential mutagenicity of these ferrocenyl derivatives re-
vealed that the compounds were inactive.  
Figure 3. Growth curves for compound 1 (top) and 3 (bottom) at 
three different concentrations (LC = 6.25 µM, MC= 12.5 µM, HC 
= 25 µM) over 4 days in cancer cell line OE 19 (n = 3 ± SD). 
Figure 4. Cellular viability (MTT, blue) and cell proliferation 
(BrdU, red) assays on colorectal cell lines (48 hours). 
In conclusion, novel ferrocenyl nucleoside analogues 1 
and 2 appear to exhibit cytostatic activities that are compa-
rable under the conditions used to commercially established 
anticancer drugs such as cisplatin and 5-FU. Control studies 
indicate that the presence of both a hydroxyl and a nucleo-
base group are required for optimal activity. This suggests a 
mechanistic role for these novel bioorganometallic com-
pounds involving an adverse affect on nucleic acid synthe-
sis, as is the case for nucleobase analogue drugs containing 
organic linker groups.12 We are currently planning to carry 
out further studies to reveal the mode of action of these fer-
ronucleosides and to highlight stereochemical and structure 
activity relationships for improving biological activity and 
specificity.  
EXPERIMENTAL SECTION  
General Information: Unless stated otherwise, all reac-
tions were performed under an Ar atmosphere. Compound 6 
was prepared as described previously.8 All tested com-
pounds had a purity of ≥95%, as shown by HPLC (see sup-
plementary information for data and conditions used).  
(R,Sp)-1-(α-N,N-Dimethylaminoethyl)-2-iodo-ferro-
cene (8). The Ugi amine 711 (4.00 g, 15.56 mmol) was dis-
solved in Et2O (50 ml) at room temperature, n-BuLi (12 ml, 
30 mmol) was added and the mixture stirred overnight. The 
reaction mixture was cooled to -78°C and iodine (9.52 g, 
37.51 mmol), dissolved in THF (60 ml), was added over 10 
min. The reaction mixture was stirred at -78°C for 90 min 
before being warmed to room temperature, at which point it 
was stirred for an additional 90 min before being quenched 
at 0°C with sodium thiosulfate(aq) (50 ml, 25% w/v). After 
dilution with Et2O (30 ml), the layers were separated and the 
aqueous layer further extracted with Et2O (3 x 50 ml). The 
combined organic fractions were dried over MgSO4, the sol-
vent removed in vacuo before purification via flash column 
chromatography (5% MeOH, 5% TEA in DCM) to yield 
product (3.18 g, 55%). 1H NMR (400 MHz, CDCl3) δ 4.46 
(dd, J = 2.4, 1.4 Hz, 1H), 4.24 (t, J = 2.6 Hz, 1H), 4.15 (dd, 
J = 2.7, 1.3 Hz, 1H), 4.12 (s, 5H), 3.62 (q, J = 6.8 Hz, 1H), 
2.15 (s, 6H), 1.50 (d, J = 6.8 Hz, 3H). 13C NMR (101 MHz, 
CDCl3) δ 90.21 (ipso Cp), 74.32 (Fc), 71.67 (Fc), 68.19 (Fc), 
65.59 (Fc), 57.59 (CH*), 45.49 (ipso Cp), 41.22 (CH3), 
16.01 (CH3). MS (ES) (m/z) calcd for C14H18N56FeI 
382.9833, found 382.9820. IR (cm-1): 3078 (=C-H), 2931 
(CH2), 2878 (CH2), 2809 (CH2), 1446 (CH3), 1371 (CH3), 
1243, 1087, 821 (CH=CH), 732 (CH Ar). Mp: 58°C-60°C.  
(R,Sp)-1-(α-Acetoxyethyl)-2-iodo-ferrocene (9). Com-
pound 8 (3.26 g, 8.51 mmol) and acetic anhydride (25.68 ml, 
272.17 mmol) were heated at 50°C for 2 hrs. The acetic an-
hydride was removed under high vacuum (0.1 mmHg) and 
the residue purified via flash column chromatography (10% 
EtOAc in hexane) to yield the yellow-brown oily product 
(2.94 g, 87%). 1H NMR (400 MHz, CDCl3) δ 5.89 (q, J = 
6.4 Hz, 1H), 4.51 (dd, J = 2.6, 1.4 Hz, 1H), 4.33 (dd, J = 2.8, 
1.4 Hz, 1H), 4.28 (t, J = 2.6 Hz, 1H), 4.15 (s, 5H), 2.01 (s, 
3H), 1.66 (d, J = 6.5 Hz, 3H). 13C NMR (101 MHz, CDCl3) 
δ 170.30 (C=O), 87.54 (ipso Cp), 75.63 (Fc), 71.76 (Fc), 
69.71 (Fc), 68.94 (Fc), 65.80 (CH*), 44.03 (ipso Cp), 21.16 
(CH3), 18.66 (CH3). IR (cm-1): 3095 (=C-H), 2972 (CH2), 
2928 (CH2), 2866 (CH2), 1729 (C=O), 1445 (CH3), 1371 
(CH3), 1085, 820 (CH=CH), 703 (CH Ar).  
 (R,Sp)-1-(α-Hydroxyethyl)-2-iodo-ferrocene (10). 
Compound 9 (2.937 g, 7.37 mmol) was dissolved in EtOH 
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 (35 ml). NaOH(aq) (30 ml, 10% w/v) was added and the re-
action was heated at 95°C for 15 min. After cooling to room 
temperature, the organic layer was extracted with EtOAc (2 
x 40 ml). The organic layers were dried over Na2SO4, the 
solvent removed in vacuo and the residue purified via flash 
column chromatography (25% EtOAc in hexane) to yield the 
yellow oily product (2.43 g, 92%) 1H NMR (400 MHz, 
CDCl3) δ 4.85 (qd, J = 6.5, 2.8 Hz, 1H), 4.46 (dd, J = 2.5, 
1.4 Hz, 1H), 4.29 (dd, J = 2.7, 1.3 Hz, 1H), 4.25 (t, J = 2.6 
Hz, 1H), 4.14 (s, 5H), 1.88 (d, J = 3.6 Hz, 1H), 1.62 (d, J = 
6.5 Hz, 3H). 13C NMR (101 MHz, CDCl3) δ 91.61 (ipso Cp), 
75.01 (Fc), 71.59 (Fc), 68.72 (Fc), 66.51 (Fc), 64.98 (CH*), 
43.62 (ipso Cp), 21.31 (CH3). MS (ES) (m/z) calcd for 
C12H13O56FeI 355.9361, found 355.9352. IR (cm-1): 3255 
(OH), 3093 (=C-H), 2967 (CH2), 2920 (CH2), 1445 (CH3), 
1369 (CH3), 1099 (C-OH), 816 (CH=CH), 684 (CH=CH).  
(R,Sp)-1-(α-Methoxyethyl)-2-iodo-ferrocene (11). 
Compound 10 (2.43 g, 6.83 mmol) was dissolved in a 
MeOH/AcOH (20 ml, 9:1) mixture and the solution was 
stirred at room temperature for 48 hrs. The reaction was 
quenched with water (10 ml) and extracted with DCM (2×20 
ml). The combined organic fractions were dried over 
MgSO4, the solvent removed in vacuo and the residue puri-
fied via flash column chromatography (25% EtOAc in hex-
ane) to yield the yellow oily product (2.37 g, 94%). 1H NMR 
(400 MHz, CDCl3) δ 4.49 (dd, J = 2.4, 1.4 Hz, 1H), 4.34 (q, 
J = 6.5 Hz, 1H), 4.29 – 4.25 (m, 2H), 4.13 (s, 5H), 3.26 (s, 
3H), 1.64 (d, J = 6.5 Hz, 3H). 13C NMR (101 MHz, CDCl3) 
δ 89.78 (ipso Cp), 74.78 (Fc), 74.22 (Fc), 71.66 (Fc), 68.86 
(Fc), 65.35 (CH*), 56.00 (CH3), 39.48 (ipso Cp), 19.63 
(CH3). MS (ES) (m/z) calcd for C13H15O56FeI 369.9517, 
found 369.9513. IR (cm-1): 3094 (=C-H), 2974 (CH2), 2926 
(CH2), 2871 (CH2), 2815 (CH2), 1448 (CH3), 1371 (CH3), 
1085 (C-O-C), 820 (CH=CH).  
 (S,Sp)-1-[α-Methyl(2-ethylpropanoate)]-2-iodo-fer-
rocene (12). Compound 11 (2.37 g, 6.42 mmol) and 1-eth-
oxyvinyloxytrimethylsilane (8.234 g, 51.37 mmol) were dis-
solved in DCM (30 ml). The mixture was cooled to -78°C 
and BF3.OEt2 (1.77 ml, 14.12 mmol) was then added drop-
wise. The reaction mixture was stirred for 15 min at -78°C 
before being warmed to room temperature and quenched 
with saturated NaHCO3 (40 ml). The organic layer was sep-
arated and the aqueous layer was further extracted with 
DCM (40 ml). The combined organic fractions were dried 
over MgSO4, the solvent removed in vacuo and the residue 
purified via flash column chromatography (10% EtOAc in 
hexane) to yield the yellow oily product (1.676 g, 61%). 1H 
NMR (400 MHz, CDCl3) δ 4.42 (dd, J = 2.4, 1.4 Hz, 1H), 
4.18 – 4.08 (m, 7H+2H), 3.14 – 3.05 (m, 1H), 2.53 (dd, J = 
15.0, 3.7 Hz, 1H), 2.11 (dd, J = 15.0, 10.3 Hz, 1H), 1.43 (d, 
J = 6.9 Hz, 3H), 1.25 (t, J = 7.2 Hz, 3H). 13C NMR (101 
MHz, CDCl3) δ 172.00 (C=O), 94.07 (ipso Cp), 74.12 (Fc), 
71.52 (Fc), 67.84 (Fc), 64.58 (Fc), 60.26 (CH2), 44.08 (ipso 
Cp), 43.19 (CH2), 30.72 (CH*), 18.90 (CH3), 14.27 (CH3). 
MS (ES) (m/z) calcd for C16H19O256FeI 425.9779, found 
425.9782. 
(S,Sp)-1-[α-Methyl-(3-(hydroxyl)propyl)]-2-iodo-fer-
rocene (13). Compound 12 (1.592 g, 3.73 mmol) was dis-
solved in Et2O (50 ml) and the solution was cooled to 0°C. 
After standing for 5 min, diisobutylalumminum hydride 
(11.2 ml, 11.2 mmol) was added slowly at that temperature. 
The mixture was stirred at 0°C for 1 hr before the reaction 
was quenched with saturated sodium potassium tartrate in 
water (30 ml). The layers were separated and the aqueous 
layer was further extracted with Et2O (30 ml). The combined 
organic fractions were dried over Na2SO4, the solvent re-
moved in vacuo and the residue purified via flash column 
chromatography (50% EtOAc in hexane) to yield the prod-
uct (1.413 g, 99%). 1H NMR (400 MHz, CDCl3) δ 4.42 (dd, 
J = 2.4, 1.4 Hz, 1H), 4.17 (td, J = 2.6, 0.6 Hz, 1H), 4.13 (s, 
5H), 4.06 (dd, J = 2.7, 1.3 Hz, 1H), 3.59 (t, J = 6.6 Hz, 2H), 
2.78 – 2.69 (m, 1H), 1.72 – 1.52 (m, 2H), 1.41 (d, J = 7.0 
Hz, 3H). 13C NMR (101 MHz, CDCl3) δ 95.87 (ipso Cp), 
73.76 (Fc), 71.47 (Fc), 67.87 (Fc), 64.18 (Fc), 60.84 (CH2), 
44.73 (ipso Cp), 42.09 (CH2), 29.81 (CH*), 19.69 (CH3). MS 
(ES) (m/z) calcd for C14H17O56FeI 383.9674, found 
383.9678. IR (cm-1): 3282 br (OH), 3088 (=CH Fc), 2971 
(CH2), 2932 (CH2), 2854 (CH2), 1556, 1452 (CH2), 1376 
(CH3), 680 (C=C). Mp: 96°C-98°C.  
(S,Sp)-1-[α-Methyl-(3-(tert-butyldiphenylsi-
lyloxy)propyl)]-2-iodo-ferrocene (14). Compound 13 
(1.413 g, 3.67 mmol) was dissolved in DCM (20 mL) at 
room temperature. TEA (0.77 ml, 5.52 mmol), tert-butyldi-
phenylsilyl chloride (1.44 ml, 5.51 mmol) and DMAP (cat-
alytic amount) were added to the mixture. The solution was 
then stirred overnight at room temperature before quenching 
with water (10 ml). The phases were separated and the aque-
ous layer was extracted with Et2O (2 x 20 ml). The combined 
organic fractions were dried over Na2SO4, the solvent re-
moved in vacuo and the residue purified via flash column 
chromatography (10% EtOAc in hexane) to yield a yellow 
oily product (2 g, 95%). 1H NMR (400 MHz, CDCl3) δ 7.70 
– 7.65 (m, 4H), 7.43 – 7.32 (m, 6H), 4.38 (dd, J = 2.4, 1.3 
Hz, 1H), 4.10 (s, 5H+1H), 4.00 (dd, J = 2.7, 1.3 Hz, 1H), 
3.70 – 3.65 (m, 2H), 2.77 – 2.68 (m, 1H), 1.88 – 1.80 (m, 
1H), 1.43 – 1.34 (m, 1H), 1.31 (d, J = 6.9 Hz, 3H), 1.05 (s, 
9H). 13C NMR (101 MHz, CDCl3) δ 135.63 (Ph), 134.10 
(ipso Ph), 134.05 (ipso Ph), 129.47 (Ph), 127.58 (Ph), 96.25 
(ipso Cp), 73.81 (Fc), 71.38 (Fc), 67.61 (Fc), 64.27(Fc), 
62.10 (CH2), 44.45 (ipso Cp), 41.60 (CH2), 30.03 (CH*), 
26.94 (tBu), 19.24 (ipso tBu), 18.91 (CH3). MS (ES) (m/z) 
calcd for C30H35O56FeISiNa 622.0851, found 622.0846. IR 
(cm-1): 3071 (=CH Fc), 2958 (CH2), 2929 (CH2), 2856 
(CH2), 1472 (CH2), 1387 (CH3), 1361, 1106, 1085, 821 (CH 
Ar TBDPS), 700 (C=C).  
(S,Sp)-1-[α-Methyl-(3-(tert-butyldiphenylsi-
lyloxy)propyl)]-2-formyl-ferrocene (15). Compound 14 
(2.182 g, 3.51 mmol) was dissolved in Et2O (30 ml), the mix-
ture was cooled to -78°C and n-BuLi (2.32 ml, 7.01 mmol) 
was added. After 30 min, DMF (0.68 ml, 8.76 mmol) was 
added and the mixture was stirred at -78°C for another 30 
min before being allowed to warm to room temperature be-
fore quenching with water (20 ml). The phases were sepa-
rated and the aqueous layer was extracted with Et2O (2 x 20 
ml). The combined ethereal fractions were dried over 
Na2SO4, the solvent removed in vacuo and the residue puri-
fied via flash column chromatography (10% EtOAc in hex-
ane) to yield the red oily product (1.686 g, 92%). 1H NMR 
(400 MHz, CDCl3) δ 10.11 (s, 1H), 7.68 – 7.59 (m, 4H), 7.42 
– 7.33 (m, 6H), 4.75 (dd, J = 2.7, 1.4 Hz, 1H), 4.48 (t, J = 
 2.6 Hz, 1H), 4.43 (dd, J = 2.6, 1.4 Hz, 1H), 4.21 (s, 5H), 3.61 
(t, J = 7.1, 2H), 3.21 – 3.10 (m, 1H), 1.73 – 1.50 (m, 2H), 
1.34 (d, J = 6.9 Hz, 3H), 1.04 (s, 9H). 13C NMR (101 MHz, 
CDCl3) δ 193.25 (C=O), 135.55 (Ph), 133.94 (ipso Ph), 
133.80 (ipso Ph), 129.55 (Ph), 127.61 (Ph), 99.14 (ipso Cp), 
76.31 (ipso Cp), 71.04 (Fc), 70.80 (Fc), 70.03 (Fc), 68.89 
(Fc), 61.75 (CH2), 43.28 (CH2), 27.90 (CH*), 26.89 (tBu), 
22.66 (ipso tBu), 19.17 (CH3). MS (ES) (m/z) calcd for 
C31H36O256FeSiNa 547.1732, found 547.1727. IR (cm-1): 
3071 (=CH Fc), 2958 (CH2), 2929 (CH2), 2856 (CH2), 1673 
(C=O), 1589 (C=N), 1427 (CH2), 1376 (tBu), 1106 (Si-OR), 
1086 (Si-OR), 821 (CH Ar Ph), 700 (C=C). 
(S,Rp)-1-[α-Methyl-(3-(tert-butyldiphenylsi-
lyloxy)propyl)]-2-vinyl-ferrocene (16). Trimethylme-
thylphosphonium bromide (1.722 g, 4.82 mmol), potassium 
tert-butoxide (0.541 g, 4.82 mmol) and a catalytic amount of 
dibenzo-18-crown-6-ether were dissolved in THF (20 ml). 
The mixture was stirred for 30 min and then 15 (1.686 g, 
3.21 mmol), dissolved in THF (30 ml), was added to the 
mixture. The reaction mixture was stirred overnight at room 
temperature, before quenching with water (10 ml) and ex-
tracting with Et2O (2 x 20 ml). The combined ethereal frac-
tions were dried over Na2SO4, solvent removed in vacuo and 
purified via flash column chromatography (5% EtOAc in 
hexane) to yield the product as a yellow oil (1.497 g, 89%). 
1H NMR (400 MHz, CDCl3) δ 7.69 – 7.63 (m, 4H), 7.44 – 
7.33 (m, 6H), 6.62 (dd, J = 17.4, 10.8 Hz, 1H), 5.34 (dd, J = 
17.5, 1.8 Hz, 1H), 5.01 (dd, J = 10.8, 1.7 Hz, 1H), 4.43 (dd, 
J = 2.5, 1.4 Hz, 1H), 4.12 (t, J = 2.6 Hz, 1H), 4.06 (dd, J = 
2.5, 1.4 Hz, 1H), 4.03 (s, 5H), 3.62 (dd, J = 7.2, 5.4 Hz, 2H), 
2.94 – 2.86 (m, 1H), 1.72 – 1.61 (m, 1H), 1.45 – 1.37 (m, 
1H), 1.30 (d, J = 6.8 Hz, 3H), 1.06 (s, 9H). 13C NMR (101 
MHz, CDCl3) δ 135.59 (Ph), 134.08 (ipso Ph), 134.02 (ipso 
Ph), 133.50 (CH vinyl), 129.49 (Ph), 127.56 (Ph), 110.96 
(CH2 vinyl), 94.84 (ipso Cp), 81.37 (ipso Cp), 69.66 (Fc), 
66.55 (Fc), 66.27 (Fc), 64.08 (Fc), 61.89 (CH2), 42.80 (CH2), 
27.65 (CH*), 26.89 (tBu), 19.23 (ipso tBu), 18.92 (CH3). MS 
(ES) (m/z) calcd for C32H38O56FeSi 522.2041, found 
522.2055. IR (cm-1): 3072 (=CH Fc), 2958 (CH2) 2930 
(CH2), 2857 (CH2), 1625 (Ar Ph), 1589, 1427 (CH2), 1388 
(CH3), 1105 (Si-OR), 1086 (Si-OR), 821 (CH Ar), 699 (vi-
nyl/C=C). 
(S,Rp)-1-[α-Methyl-(3-(tert-butyldiphenylsi-
lyloxy)propyl)]-[2-(hydroxyl)ethyl]-ferrocene (17). Com-
pound 16 (1.497 g, 2.87 mmol) was dissolved in THF (30 
ml). BH3.THF (1M, 8.2 ml, 8.2 mmol) was then added drop-
wise at room temperature and the mixture stirred for 2 hrs. 
EtOH (9.76 ml), NaOH (3M, 9.76 ml, 29.28 moles) and 
H2O2 (30 wt. % in water, 7.17 ml, 63.24 moles) were then 
successively added and the mixture stirred for 1 hr at room 
temperature. The reaction mixture was extracted with DCM 
(30 ml), washed with brine (20 ml) and then dried over 
Na2SO4. The solvent was removed in vacuo and the residue 
purified via flash column chromatography (10% EtOAc in 
hexane) to yield the yellow oily product (1.434 g, 82%). 1H 
NMR (400 MHz, CDCl3) δ 7.68 – 7.64 (m, 4H), 7.43 – 7.36 
(m, 6H), 4.11 – 4.09 (m, 1H), 4.05 (s, 5H), 4.00 (t, J = 2.5 
Hz, 1H), 3.97 (dd, J = 2.5, 1.3 Hz, 1H), 3.75 (tq, J = 6.8, 2.6 
Hz, 2H), 3.67 – 3.63 (m, 2H), 2.77 – 2.68 (m, 1H), 2.66 – 
2.49 (m, 2H), 1.74 – 1.66 (m, 1H), 1.43 – 1.32 (m, 1H), 1.26 
(d, J = 6.8 Hz, 3H), 1.06 (s, 9H). 13C NMR (101 MHz, 
CDCl3) δ 135.56 (Ph), 133.96 (ipso Ph), 129.59 (Ph), 127.63 
(Ph), 95.01 (ipso Cp), 82.31 (ipso Cp), 69.03 (Fc), 67.36 
(Fc), 65.39 (Fc), 65.15 (Fc), 63.00 (CH2), 61.98 (CH2), 42.43 
(CH2), 30.93 (CH2), 27.51 (CH*), 26.91 (tBu), 19.37 (CH3), 
19.22 (ipso tBu). MS (ES) (m/z) calcd for C32H40O256FeSiNa 
563.2045, found 563.2039. IR (cm-1): 3378 br (OH), 3072 
(=CH Fc), 2930 (CH2), 2857 (CH2), 1589, 1472 (CH3), 1427 
(CH2), 1388 (tBu), 1361, 1105 (Si-OR), 1086 (Si-OR), 819 
(CH Ar Ph), 705 (C=C). HPLC: retention time 16.85 min; 
chiral AD column, 1% IPA in hexane, isocratic over 40 min 
(1 mL/min), ee 97%. 
(S,Rp)-1-[α-Methyl-(3-(hydroxy)propyl)]-2-
[(thyminyl)ethyl]-ferrocene (1). Triphenylphosphine (137 
mg, 0.516 mmol), 3-benzoyl thymine13 (95 mg, 0.447 mmol) 
and compound 17 (0.186 g, 0.344 mmol) were dissolved in 
THF (10 ml) and stirred for 10 min at room temperature. The 
flask was then covered with foil and DIAD (0.11 ml, 0.516 
mmol) was added at room temperature before the mixture 
was heated at 65°C for 2 hrs. The reaction mixture was evap-
orated, extracted with EtOAc (30 ml), washed with brine (20 
ml) followed by water (20 ml) and dried over Na2SO4. The 
solvent was removed in vacuo and the residue purified via 
flash column chromatography (30% EtOAc in hexane) to 
give the fully protected product (219 mg, 85%). Deprotec-
tion was achieved firstly by stirring the compound in 5 ml of 
TBAF for 2 hr before the solvent was removed. The mixture 
was then redissolved in methylamine (33 wt. % in ethanol, 2 
ml) and stirred at room temperature for an addition 30 min. 
The methylamine was evaporated and the crude was purified 
via flash column chromatography (5% MeOH in DCM) to 
give the product as a yellow oil (105 mg, 74%). 1H NMR 
(400 MHz, CDCl3) δ 9.44 (s, 1H), 7.07 (d, J = 1.2 Hz, 1H), 
4.16 – 4.02 (m, 8H), 3.99 – 3.88 (m, 1H), 3.74 – 3.55 (m, 
3H), 2.96 – 2.47 (m, 4H), 1.95 (d, J = 1.1 Hz, 3H), 1.75 – 
1.64 (m, 1H), 1.56 – 1.46 (m, 1H), 1.39 (d, J = 6.8 Hz, 3H). 
13C NMR (101 MHz, CDCl3) δ 164.22 (C=O), 151.11 
(C=O), 140.41 (CH-thymine), 111.00 (ipso thymine), 95.36 
(ipso Fc), 80.77(ipso Fc), 69.30 (CH Cp), 67.63 (CH Cp), 
65.97 (CH Cp), 65.37 (CH Cp), 60.27 (CH2), 49.84 (CH2), 
43.24 (CH2), 27.99 (CH2), 27.07 (CH), 19.25 (CH3 thymine), 
12.30 (CH3). MS (ES) (m/z) calcd for C21H26N2O3Na56Fe 
433.1191, found 433.1182. IR (cm-1): 3520-3291 br (OH), 
2957 (CH), 1677 (C=O). 
 (S,Rp)-1-[α-Methyl-(3-(hydroxy)propyl)]-2-[2-(-ad-
enin-9-yl)ethyl]-ferrocene (2). Triphenylphosphine (0.291 
g, 1.109 mmol), N,N-6-dibenzoyl-adenine14 (0.381 g, 1.109 
mmol) and compound 17 (0.300 g, 0.555 mmol) were dis-
solved in THF (10 ml) and stirred for 10 min at room tem-
perature. The flask was then covered with foil and DIAD 
(0.24 ml, 1.109 mmol) was added at room temperature be-
fore the mixture was warmed up to 65°C for 2 hrs. The reac-
tion mixture was evaporated, extracted with EtOAc (30 ml), 
washed with brine (20 ml) followed by water (20 ml) and 
dried over Na2SO4. The solvent was removed in vacuo and 
the residue purified via flash column chromatography (30% 
EtOAc in hexane) to give the protected product (0.343 g, 
72%). Deprotection was achieved firstly by stirring the com-
pound in TBAF (5 ml, 1M) for 2 hr. The solvent was then 
removed and the residue redissolved in methylamine (33 wt. 
 % in ethanol, 2 ml) and stirred at room temperature for an 
additional 30 min. The methylamine was then evaporated 
and the crude mixture purified via flash column chromatog-
raphy to give the product as a yellow solid (170 mg, 73%). 
1H NMR (400 MHz, DMSO-d6) δ 8.19 (s, 1H), 8.17 (s, 1H), 
7.21 (s, 2H), 4.41 – 4.33 (m, 2H+1H (OH)), 4.11 (s, 5H), 
4.02 (d, J = 2.4 Hz, 2H), 3.99 (t, J = 2.4 Hz, 1H), 3.42 – 3.28 
(m, 2H), 2.97 – 2.75 (m, 2H), 2.75 – 2.67 (m, 1H), 1.53 – 
1.45 (m, 1H), 1.32 (d, J = 6.8 Hz, 3H+1H). 13C NMR (101 
MHz, DMSO-d6) δ 155.95 (ipso adenine), 152.43 (CH ade-
nine), 149.39 (ipso adenine), 140.71 (CH adenine), 118.75 
(ipso adenine), 94.43 (ipso Cp), 81.89 (ipso Cp), 68.80 (Cp), 
66.46 (Cp), 64.92 (Cp), 64.74 (Cp), 58.66 (CH2), 43.10 
(CH2), 42.43 (CH2), 27.98 (CH2), 27.10 (CH*), 19.38 (CH3). 
MS (ES) (m/z) calcd for C21H26N5O56Fe 420.1487, found 
420.1484. IR (cm-1): 3348 br (OH), 3270 (NH2), 3240 (NH2), 
3098 (=CH Fc), 2955 (CH2), 2926 (CH2), 2871 (CH2), 1674 
(C=N), 1604 (NH2), 1574 (NH2), 1305 (OH), 1076 (C-O), 
814 (CH Ar). Mp: 90°C-92°C.  
1-[α-Methyl-(3-(hydroxy)propyl)]ferrocene (3). (S)-3-
Ethoxy-1-methyl-3-oxopropylferrocene15 (220 mg, 0.733 
mmol) was dissolved in diethyl ether (10 ml). LiAlH4 (56 
mg, 1.466 mmol) was added carefully and the resulting sus-
pension was left to stir for 1 hr. The reaction was quenched 
with saturated sodium potassium tartrate (10 ml), extracted 
with diethyl ether (2 x 20ml), dried over MgSO4 and the sol-
vent removed in vacuo. The residue was purified via flash 
column chromatography to give the product as a yellow oil 
(100 mg, 58%). 1H NMR (300 MHz, CDCl3) δ 4.13 (s, 5H), 
4.09 – 4.04 (m, 4H), 3.67 (q, J = 6.2 Hz, 2H), 2.74 – 2.53 
(m, 1H), 1.85 – 1.61 (m, 2H), 1.27 (d, J = 6.9 Hz, 3H). 13C 
NMR (101 MHz, CDCl3) δ 95.41 (ipso Cp), 68.51 (CH Cp), 
67.22 (CH Cp), 67.12 (CH Cp), 67.07 (CH Cp), 65.70 (CH 
Cp), 61.12 (CH2), 41.47 (CH2), 29.62 (CH), 20.64 (CH3). 
MS (ES) (m/z) calcd for C14H18O256Fe 258.0707, found 
258.0708. IR (cm-1): 3512-3146 br (OH), 2933 (CH), 1052 
(C-O). 
1-(Thyminyl-)ethyl-ferrocene (4). Triphenylphosphine 
(348 mg, 1.30 mmol), N-3-benzoylthymine13 (223 mg, 1.04 
mmol), and 2-ferrocenylethanol16 (200 mg, 0.87 mmol) were 
dissolved in THF (10 ml) and stirred for 10 min at room tem-
perature. The flask was then covered with foil and DIAD 
(0.28 ml, 1.30 mmol) was added at room temperature before 
the mixture was heated at 65°C for 2 hrs. The solvent was 
then evaporated and the residue extracted with EtOAc (30 
ml), washed with brine (20 ml) and water (20 ml) and dried 
over Na2SO4, before the solvent was removed in vacuo. 
Deprotection was achieved by treating the crude mixture 
with methylamine solution (33 wt. % in ethanol, 5 ml) for 30 
min. The solvent was then evaporated in vacuo and the resi-
due purified via flash column chromatography (40% EtOAc 
in hexane) to give the product (176 mg, 60%). 1H NMR (300 
MHz, CDCl3) δ 8.29 (s, 1H), 6.70 (d, J = 1.2 Hz, 1H), 4.15 
(s, 5H), 4.13 – 4.09 (m, 2H), 4.04 (t, J = 1.8 Hz, 2H), 3.79 
(t, J = 7.1 Hz, 2H), 2.73 (t, J = 7.1 Hz, 2H), 1.85 (d, J = 1.2 
Hz, 3H). 13C NMR (101 MHz, CDCl3 trace of MeOD) δ 
216.94 (ipso thymine), 193.73 (C=O), 181.71 (C=O), 141.17 
(CH-thymine), 83.57 (ipso-Cp), 68.63(CH-Cp), 68.37(CH-
Cp), 67.94 (CH-Cp), 50.20 (CH2), 29.17 (CH2), 11.98 (CH3). 
MS (ES) (m/z) calcd for C17H18N2O256Fe 338.0718, found 
338.0720. Mp: degraded at 235°C. IR (cm-1): 3146 (NH), 
2999 (CH), 1683 (C=O), 1644 (NH bending). 
1-[2-(Adenin-9-yl)ethyl]-ferrocene (5). Tri-
phenylphosphine (0.383 g, 1.46 mmol), N,N-6,6-dibenzoyl-
adenine14 (0.500 g, 1.46 mmol) and 2-ferrocenylethanol16 
(0.201 g, 0.73 mmol) were dissolved in THF (10 ml) and 
stirred for 10 min at room temperature. The flask was then 
covered with foil and DIAD (0.24 ml, 1.18 mmol) was added 
at room temperature before the mixture was warmed up to 
65°C for 2 hrs. The reaction mixture was evaporated, ex-
tracted with EtOAc (30 ml), washed with brine (20 ml) fol-
lowed by water (20 ml) and then dried over Na2SO4. The 
solvent was removed in vacuo and purified via flash column 
chromatography (40% EtOAc in hexane) to give the bis-pro-
tected product (0.134 g, 33%). Deprotection was achieved 
by dissolving the compound (0.055 g, 0.1 mmol) in methyl-
amine (33 wt. % in ethanol, 3 ml) and stirring at room tem-
perature for 30 min. The methylamine was then evaporated 
and the residue purified via flash column chromatography 
(95/5 DCM/MeOH) to give the product as a yellow solid 
(0.019 g, 58%). 1H NMR (400 MHz, DMSO-d6) δ 8.17 (s, 
1H), 8.05 (s, 1H), 7.17 (s, 2H), 4.31 (dd, J = 8.2, 6.8 Hz, 2H), 
4.15 (s, 5H), 4.08 – 4.02 (m, 4H), 2.85 (t, J = 7.5 Hz, 2H). 
13C NMR (101 MHz, DMSO-d6) δ 155.89 (ipso adenine), 
152.35 (CH adenine), 149.40 (ipso adenine), 140.76 (CH ad-
enine), 118.73 (ipso adenine), 84.39 (ipso Cp), 69.00 (Fc), 
68.55 (Fc), 43.75 (CH2), 29.34 (CH2). MS (ES) (m/z) calcd 
for C17H18N556Fe 348.0912, found 348.0920 (M+ + H+). IR 
(cm-1): 3399 (NH2), 3316 (NH2), 3084 (=CH Fc), 2980 
(CH2), 2931 (CH2), 2907 (CH2), 1653 (C=C), 1596 (NH2), 
1435 (CH2), 1245, 797 (CH Ar). Mp: 142°C (decomp). 
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